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ABSTRACT
Objectives: The primary risk of abdominal aortic aneurysms (AAAs) is
rupture, which is associated with a high mortality rate. Elective surgical
options for AAA include open repair (OR) and endovascular aneurysm
repair (EVAR). EVAR is less invasive than OR, and therefore may have less
surgical risk than OR. However, the graft used for EVAR is much more
expensive then the graft used for OR.
Methods: A decision model with a 10-year time horizon was used to
assess the cost-effectiveness of EVAR versus OR. The primary out-
come measure was quality-adjusted life-years (QALYs). The model incor-
porated the costs and beneﬁts of both perioperative outcomes and
postoperative outcomes. A systematic review was conducted to derive
clinical outcome rates. Cost and utility model variables were based on
various literature sources and data from a recent Canadian observational
study. Parameter uncertainty was assessed using probabilistic sensitivity
analysis.
Results: In the base-case model, the incremental cost per QALY of EVAR
was estimated to be $268,337, whereas the incremental cost per life-year
was found to be $444,129. The incremental cost per QALY of EVAR
remained above $295,715 under different assumptions of cohort age and
model time horizon.
Conclusions: Based on commonly quoted willingness-to-pay thresholds,
EVAR was not found to be cost-effective compared to OR.
Keywords: abdominal aortic aneurysm, cost-effectiveness analysis, endo-
vascular repair, Markov model, open surgical repair.
Introduction
Abdominal aortic aneurysms (AAAs) are a signiﬁcant health
concern in Canada. It is estimated that the prevalence of AAA
ranges from 4.1% to 14.2% in men, and between 0.35% and
6.2% in women [1]. In Canada, AAAs are the 10th leading
cause of death in men 65 years of age or older. The primary risk
of AAA is rupture, which is associated with high mortality rates
[2]. As a result of these high mortality rates, surgery is recom-
mended when aneurysms are >5.5-cm diameter, when aneu-
rysms are symptomatic or when there has been a rapid increase
in aneurysm size.
Current elective surgical treatment options for AAA include
open repair (OR) and endovascular aneurysm repair (EVAR).
Endovascular repair is less invasive than OR, which may result in
a better quality of life for patients after surgery. Recent random-
ized controlled trials [3,4] have shown EVAR to have lower
30-day mortality and fewer serious operative complications com-
pared to OR.
As with most new health technologies, there is a trade-off
between the costs and beneﬁts of endovascular repair. A recent
Canadian hospital-based cost study estimated the cost per EVAR
graft to be $9500 compared to $374 for an OR graft [5]. This
additional cost may be partially offset by a shorter length of stay.
Forbes et al. found the mean length of hospital stay after EVAR
to be 5.1 days shorter compared to OR [5]. An additional cost
consideration relates to the concern that postprocedural compli-
cations may arise after EVAR. These include endoleaks, graft
migration, aneurysm rupture, and conversion to OR.
This study evaluates the cost-effectiveness of EVAR versus
OR in Canada, using a decision analytic framework. A system-
atic literature review was conducted to estimate clinical model
parameters. Cost and utility model parameters for the model
were estimated from various published literature sources along
with data from a recent Canadian observational study [6].
Methods
Overview
A probabilistic, decision analytic model was used to estimate
the expected costs, life-years, and quality-adjusted life-years
(QALYs) associated with two treatment options for elective AAA
repair: 1) EVAR and 2) OR. The model cohort is comprised of
70-year-old male patients with >5.5-cm AAAs, who are medi-
cally suitable to undergo either EVAR or OR. This speciﬁc age
was chosen as a recent Canadian study [2] presenting historical
data on AAA repair reported that the average age of AAA
patients was close to 70 years. The analysis is performed from
a third-party health care payer perspective. The time horizon of
the model is 10 years, however, alternative time horizons are
explored in sensitivity analysis. Both costs and outcomes were
discounted at 3% annually. The overall approach of the analysis
will be, ﬁrst, to determine whether one strategy is dominant
(lower costs, more QALYs) over the other. In the absence of
dominance, an incremental cost-effectiveness ratio will be calcu-
lated and expressed as an incremental cost per QALY gained.
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Model Structure
The model includes both a 30-day postoperative phase and a
long-term Markov model phase. The structure of the short-term
phase of the model is shown in Figure 1. During the 30-day
postoperative phase, both treatment arms are at risk for opera-
tive death and postoperative complications. In addition, the
EVAR treatment arm is at risk for conversion to OR along with
endoleaks. Four postoperative complications with associated
long-term cost, mortality, and morbidity impacts were included
in the model. These complications were stroke, myocardial inf-
arction (MI), renal failure, and congestive heart failure (CHF).
The proportion of patients suffering a complication or operative
death differs between the OR and EVAR treatment arms. The
30-day model phase estimates the expected costs of the index
hospitalization along with expected QALYs over 30 days for the
two treatment arms.
Figure 2 displays the long-term phase of the model. The
long-term phase is structured as a Markov model with cycles of
3 months in duration. Patients transition between a number of
health states during each cycle. Patients who suffer a post-
operative complication continue in a single “alive” health state
until they die. Separate probabilities of death, utility values,
and costs are assigned to the stroke, MI, renal failure, and CHF
“alive” health states. Patients in the EVAR treatment arm who
did not have a postoperative complication transition between
the four health states in the long-term model. These long-term
health states are aneurysm rupture, endoleak, conversion to
OR, death, and post-EVAR no events. Patients who do not
immediately die after rupture are converted to OR and are at
risk for postoperative complications. Patients in the OR treat-
ment group without a postoperative complication transition
between aneurysm rupture, death, and post-OR no-events
health states. There are unique costs and QALYs associated
with each health state.
Model Input Parameters
Various sources were used for the model input parameters. A
systematic literature review was conducted to identify studies
that estimate the 30-day clinical outcomes such as postoperative
death and complication rates for the two treatment arms. Long-
term model parameters were derived from a combination of our
primary systematic review, peer-reviewed studies, government
publications, and administrative databases. A substudy using
data from an observational Canadian study was conducted to
estimate the cost of the index hospitalization [6].
A systematic literature review was conducted to identify
studies that derive 30-day postoperative and certain long-term
clinical model parameters (endoleaks, conversion to OR, and
aneurysm rupture). The initial literature search identiﬁed 3946
unique citations with EVAR or OR in their title or abstract. The
ﬁnal screen of articles revealed 84 unique primary studies com-
paring EVAR to OR (six randomized control trials [RCTs] and
78 observational studies). These studies formed the basis of the
data used for the clinical model parameters. Analyses were per-
formed separately for the RCT studies and for the observational
studies. When available, estimates from the RCT studies were
used in the model. When outcomes were reported in more than
one study, pooled estimates of the probabilities of events were
made separately for EVAR and OR. Pooling was carried out
using random effects inverse variance weighting techniques [7].
Data from RCTs were available for all model variables except
for postoperative stroke and annual long-term conversion from
EVAR to OR estimates.
Annual mortality rates for the long-term part of the model
were derived from a number of sources. The annual probability of
death for all causes by age was based from the Statistics Canada
life tables [8]. It was assumed that patients who were treated for
AAA would have a higher risk of death compared to the general
population. The long-term relative risk of death for AAA patients
compared to the general population (i.e., relative risk, 1.3) was
based on reported ﬁndings from a recent Canadian study [6]. The
probability of death after rupture was based on a study by Harris
et al. [9]. The absolute risk of death post-MI and poststroke was
based on studies by Kapral et al. [10] and Rouleau et al. [11],
respectively. The relative risk of death after CHF and renal failure
was taken from a study by Herzog et al. [12].
Figure 1 Structure of 30-day postoperative decision tree.
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Based on data collected for a Canadian observational study
[6], a substudy was conducted to estimate the costs of the index
hospitalization for the EVAR and OR treatment arms. In this
substudy, detailed inpatient costing records were obtained from a
southern Ontario hospital for consecutive patients undergoing
either elective EVAR (n = 140) or OR (n = 195) from August
2003 to April 2005. Total hospital costs included those related to
the aneurysm procedure and device, other tests and procedures,
length of stay, and drugs. Surgeons’ and anesthetists’ fees related
to the OR and EVAR procedures were added based on the
Ontario Schedule of Physician Beneﬁts [13].
For each hospitalization, data were available on any postop-
erative complications that occurred. The entire cohort of each
strategy in the model was assigned the mean costs of hospitaliza-
tions inwhich a postoperative complication (stroke,MI, CHF, and
renal failure) did not take place. The proportion of the model
cohort that incurred a complication was assigned additional costs
for their index hospitalization. These additional costs were based
on further analysis of the patient cost records. Speciﬁcally, the
additional hospital costs were estimated using an ordinary least
squares regression model. In this model, patient hospital cost was
speciﬁed as the dependant variable, whereas indicator variables
for treatment, postoperative death, and other postoperative com-
plications (stroke, MI, CHF, and renal failure) were speciﬁed as
dependant variables. This provided an estimate of the additional
cost of having each complication during the initial hospitalization.
A number of cost variables were used for the long-term phase
of the model. Based on expert opinion of a vascular surgeon, it
was assumed that EVAR patients would be followed up with one
computed tomography (CT) scan annually. Therefore, the annual
follow-up cost of EVAR included the costs of one CT scan and
one vascular surgeon assessment. The cost of CT scan was pro-
vided by a teaching hospital in southern Ontario. The cost of a
vascular surgeon assessment was derived from the Ontario
Schedule of Physician Beneﬁts [13]. No annual follow-up costs
were assigned to OR patients. The cost applied to aneurysm
rupture repair was based on the mean cost of rupture repair
hospitalization found in the Ontario Case Costing Initiative data-
base [14]. The cost of an endoleak intervention was based on the
cost for an embolization reported in a recent Canadian study [5].
The annual costs of postmajor complications (MI, CHF, stroke,
and renal failure) were derived from various Canadian literature
sources. The annual cost of CHF was based on a study by
Tsuyuki et al. [15] in which the 6-month cost of hospitalized
patients with heart failure was estimated. The annual cost after
MI was derived from an unpublished study by Coyle et al. The
annual costs after renal failure and stroke were derived from
Kroeker et al. [16] and Riviere et al. [17], respectively.
Background utility values by age were based on general popu-
lation utility values for males estimated by Kind et al. [18].
Differences in utility values between EVAR and OR were based
on data reported in the EVAR-1 study [3]. In this study, the mean
EQ5D index utility scores were reported for patients randomized
to either EVAR (n = 543) or OR (n = 539) at various time
periods. Speciﬁcally, utility values were reported at baseline, from
months 0 to 3, from months 3 to 12, and from months 12 to 24.
Utility decrements were applied to background utility values and
were used to estimate the mean utility for the time periods used
in our model. During the long-term phase of the model, the
proportion of the treatment cohorts that had suffered a postop-
erative complication was assigned further utility decrements. The
utility weights assigned to the various disease states are shown in
Table 1. The utility weights for stroke and MI health states were
derived from Schleinitz and Heidenreich [19] and Oldridge et al.
[20], respectively. The utility weights for renal failure and CHF
health states were derived from Revicki [21] and Lewis et al.
[22]. These weights were multiplied by the no-complications
daily utility weight for each treatment group.
Calibrating Long-Term Survival Estimates
The all-cause long-term mortality reported in the Dutch Ran-
domized Endovascular Aneurysm Management (DREAM) and
EVAR-1 trials were reviewed and used to calibrate the long-term
Figure 2 Structure of long-term Markov model.
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mortality estimates of the model. Speciﬁcally, the long-term mor-
tality rates used in the model for OR and EVAR were modiﬁed in
order for cumulative mortality rates for OR and EVAR to reﬂect
the trials’ ﬁndings. Long-term mortality was assumed to remain
identical for both OR and EVAR after convergence. Further-
more, the long-term costs and utility decrements associated with
postoperative complications (i.e., stroke, MI, renal failure, and
CHF) were limited to the time when cumulative mortality rates
converge.
Sensitivity Analysis and Parameter Uncertainty
One-way sensitivity analyses were performed to assess the impact
of a number of structural assumptions and alternative patient
subgroups on the model results. Speciﬁcally, the model was run
with alternative time horizons, starting ages, postoperative com-
plication rates, reintervention costs, long-term utility values, and
discount rates.
Parameter uncertainty is addressed by means of probabilistic
sensitivity analysis (PSA). In PSA, model variables are assigned
distributions of values around their mean instead of single-point
estimates. The model is run many times in what is referred to as
Monte Carlo simulations. Each time the model is run, a different
set of values from all model parameters is chosen based on the
speciﬁed distributions and a set of random numbers. Different
expected costs and outcomes are estimated in each simulation.
When the model is runmany times, an assessment of the impact of
parameter uncertainty of all model variables on cost-effectiveness
can be made. Parameter uncertainty is expressed as cost-
effectiveness acceptability curves (CEACs). CEACs present the
probability that a treatment is cost-effective than its comparators
as a function of willingness to pay (WTP) for the outcome of
interest.
In the current model, beta distributions were assumed for all
probability and utility variables. Gamma distributions were
assumed for all cost variables, whereas lognormal distributions
were assumed for all relative risk parameters.
Results
Model Input Variable Values
Table 2 provides a summary of the model input parameters used
in the 30-day short-term phase of the model. Table 1 provides a
summary of the model input parameters used in the long-term
Markov phase of the model. As shown in Table 2, estimates of
postoperative mortality are 1.47% for EVAR and 4.4% for OR.
The probability of postoperative complications is estimated to
be higher for OR compared to EVAR. The biggest difference is
found in MI and CHF. The probability of both postoperative
complications is estimated to be 5.3% for OR compared to 3.5%
for EVAR. The utility decrement for OR applied in the 30-day
phase of the model was 0.06 (0.73 for EVAR and 0.67 for open
surgical repair [OSR]).
The cost of a hospitalization for EVAR in the absence of
complications was estimated to be $26,985, whereas the cost for
a hospitalization for OR was estimated to be $15,358. If patients
incurred a postoperative complication, additional costs were
added. For example, the additional hospital cost of having post-
operative renal failure was estimated to be $32,537. Therefore,
the costs assigned to the proportion of the cohort with post-
operative renal failure in the OR arm would be $47,895
($15,358 + $32,537).
As shown in Table 1, ﬁndings from our systematic review
were used to estimate the annual probability of EVAR treatment
arm experiencing endoleak, converting to OR, and for both
treatment groups experiencing an aneurysm rupture. Based on
Table 1 Annual long-term model inputs
Model variable
Point
estimate Distribution
Conversion from EVAR to OR 0.66% Beta (a = 49.7, b = 7,486.26)
Endoleaks 2.6% Beta (a = 24.4, b = 912.2)
Rupture (EVAR) 0.8% Beta (a = 24.8, b = 3,075.26)
Rupture (OR) 0% —
Mortality
All causes Depends
on age
—
Relative risk (general
population)
1.3 —
After rupture 65% Beta (a = 9.3, b = 5.0 )
MI 5.3% Beta (a = 168.4, b = 3,010)
Stroke 12% Beta (a = 350.9, b = 2,573.1)
Renal failure (relative risk) 2.24 Lognormal (m = 0.81, a = 0.008)
CHF (relative risk) 1.64 Lognormal (m = 0.81, a = 0.008)
Costs ($)
Follow-up costs (EVAR) 352 Gamma (a = 25, b = 14.1)
Rupture repair 17,212 Gamma (a = 25, b = 688.5)
Endoleak repair 900 Gamma (a = 25, b = 36.0)
Stroke 15,690 Gamma (a = 25, b = 627.6)
MI 5,566 Gamma (a = 25, b = 222.6)
Renal failure 57,314 Gamma (a = 25, b = 2,292.6)
CHF 9,096 Gamma (a = 25, b = 363.8)
Background utility by age
<55 0.84 —
55–64 0.78 —
65–75 0.78 —
>75 0.75 —
Utility weights
No complications 0.71 Beta (a = 385.3, b = 157.5)
Stroke 0.39 Beta (a = 39, b = 61)
MI 0.77 Beta (a = 77, b = 23)
Renal failure 0.63 Beta (a = 63, b = 37)
CHF 0.64 Beta (a = 64, b = 36)
EVAR, endovascular aneurysm repair; OR, open repair; MI, myocardial infarction; CHF,
congestive heart failure.
Table 2 Thirty-day postoperative model inputs
Model variable
Point
estimate Distribution
Postoperative death (EVAR) 1.47% Beta (a = 11.7, b = 777.1.8)
Postoperative death (OR) 4.% Beta (a = 32.9, b = 714.9)
Conversion from EVAR to
OR
1.8% Beta (a = 13.8, b = 753.4)
Postoperative complications
Stroke (EVAR) 0.1% Beta (a = 1.2, b = 1,232.1)
Stroke (OR) 0.15% Beta (a = 24.9, b = 16,617.7)
MI (EVAR) 3.5% Beta (a = 24.1, b = 665.1)
MI (OR) 5.3% Beta (a = 23.3, b = 423.0)
Renal failure (EVAR) 0.0% —
Renal Failure (OR) 0.57% Beta (a = 24.9, b = 4,336.1)
CHF (EVAR) 3.5% Beta (a = 24.1, b = 665.1)
CHF (OR) 5.3% Beta (a = 23.6, b = 423.0)
Utility weights
Utility decrement for OR 0.06 Beta (a = 38.1, b = 504.91)
Hospitalization costs ($)
No postoperative
complications (EVAR)
26,985 Gamma (a = 25, b = 1,079.4)
No postoperative
complications (OR)
15,358 Gamma (a = 460.6, b = 33.3)
Renal failure Add 32,537 Gamma (a = 25, b = 1,301.4)
CHF Add 3,211 Gamma (a = 1.1, b = 2,927.7)
MI Add 755 Gamma (a = 0.03, b = 23,485.2)
Stroke Add 10,908 Gamma (a = 0.54, b = 19,906.3)
Death Add 15,916 Gamma (a = 8.1, b = 1,969.6)
EVAR, endovascular aneurysm repair; OR, open repair; MI, myocardial infarction; CHF,
congestive heart failure.
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the meta-analysis, the model assumed the annual probability of
rupture to be 0% for the OR treatment arm and 0.8% for the
EVAR treatment arm. The model assumed the annual probability
of endoleaks to be 2.6%, and the probability of conversion from
EVAR to OR to be 0.66%. Although the DREAM study [23]
found the mean utility for OR to be slightly higher than EVAR
(0.72 vs. 0.71), no utility decrement was applied. In sensitivity
analysis, OR was assumed to have 0.01 higher utility than EVAR
during the long-term phase of the model. The cost of an aneu-
rysm rupture is estimated to be $17,212. The annual cost of MI,
CHF, stroke, and renal failure was estimated to be $5,566,
$9,096, $15,690, and $57,314, respectively.
Calibrating Long-Term Survival Estimates
Survival beyond 1 year was reported in both the EVAR-1 [3]
and the DREAM [23] trials. Both trials found that cumulative
all-cause mortality for EVAR and OR converged after appro-
ximately 2 years. Based on these ﬁndings, we calibrated the
long-term all-cause mortality rate of OR so that cumulative
mortality rates for the two groups converge at 2 years. Figure 3
presents the cumulative survival rates over time for EVAR and
OR predicted by the model, assuming a starting cohort of
70-year-old males. As shown in this Figure, the model predicts
that cumulative survival is identical for OR and EVAR after 2
years. The four-year cumulative mortality predicted by the
model was 21% for both EVAR and OR groups, which com-
pares to a four-year mortality of 26% as reported in EVAR-1.
This difference is mainly due to the age of model entry. If the
model cohort is assumed to be 74 years old (average age in
EVAR-1) instead of 70 years of age, the four-year predicted
mortality rate becomes 27%.
Cost-Effectiveness Results
Base-case. Expected costs, life-years, and QALYs for the EVAR
and OR treatment arms are presented in Table 3. Over a time
horizon of 10 years, the expected cost of EVAR was estimated to
be $31,908, whereas the expected cost of OR was estimated to be
$18,522. The EVAR treatment arm was estimated to produce
0.03 more life-years and 0.05 more QALYs compared to OR.
Using life-years gained as the outcome measure, the incremental
cost-effectiveness of EVAR was estimated to be $444,129. The
incremental cost per QALY was estimated to be $268,337.
Figures 4 and 5 present the cost-effectiveness acceptability curves
for the cost per life-year gained and the cost per QALY gained
outcomes. Based on the life-years outcome, the probability that
EVAR is cost-effective is 0.02 at a WTP threshold of $50,000 per
life-year, and 0.03 at a WTP threshold of $100,000 per life-year.
Based on the QALY outcome, the probability that EVAR is
cost-effective is 0.03 at a WTP threshold of $50,000 per QALY,
and 0.07 at a WTP threshold of $100,000 per QALY.
Sensitivity analyses. Cost-effectiveness results based on a
number of sensitivity analyses are presented in Table 4. Chang-
ing the time horizon has a relatively small impact on cost-
effectiveness. Using a 5-year time horizon, the expected cost per
QALY is estimated to be $240,355. If the time horizon is
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Figure 3 Survival predicted by model.
Table 3 Base-case results
Treatment arm
Expected values ICER
Costs ($) LYs QALYs $ per LY $ per QALY
EVAR 31,908 6.631 5.063 — —
OR 18,552 6.601 5.014 — —
Incremental (EVAR/OR) 13,355 0.030 0.050 444,129 268,337
EVAR, endovascular aneurysm repair; OR, open repair; LY, life-years; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
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extended to 20 years, the incremental cost per QALY of EVAR
is $287,257.
The starting age of the cohort had a marginal impact on
cost-effectiveness results. The cost per QALY for EVAR when the
starting cohort is assumed to be 50 years old is $247,006,
whereas the cost per QALY assuming an 80-year-old starting
cohort is $363,148. Changing the discount rate used in the model
had a minimal impact on model results.
If the 30-day postoperative complication rates for EVAR are
assumed to be the same as the OR rates, the cost per QALY is
$503,335. If the long-term utility value for OR is assumed to be
0.01 higher than it is for EVAR, OR becomes dominant (more
QALYs, less costs) compared to EVAR. If it is assumed that all
endoleak interventions would require a complete EVAR redo
(i.e., using a cost of $26,985 instead of $900), the incremental
cost per QALY of EVAR compared to OR becomes $349,450.
Discussion
Our model provides a Canadian speciﬁc assessment of the long-
term cost-effectiveness of elective endovascular repair of aortic
aneurysms compared to elective OR. There are a number of
strengths to our current analysis. Key clinical model parameters
(30-day postoperative death and complication rates, annual
rupture, annual endoleak, and annual conversion to OR rates)
were determined primarily through a formal systematic review
and meta-analysis of recently published RCTs. In the absence of
RCTs, nonrandomzied data were used. Cost variables used in the
model were all based on Canadian studies including a recent
observational study of patients undergoing EVAR and OSR of
AAAs. In addition, uncertainty surrounding the values of the
model parameters was incorporated and assessed using a com-
prehensive probabilistic analysis.
In our base-case analysis, we estimated the incremental cost
per QALY of EVAR to be $268,337. Based on common WTP
thresholds, this would not be considered cost-effective. Our ﬁnd-
ings are similar to other recent economic models comparing
elective EVAR to OR of AAAs. For example, Michaels et al. [24]
found the incremental cost-effectiveness of EVAR compared to
OR to be £110,000 per QALY in patients suitable for OR. Based
on a currency exchange rate of £2.03 per CDN$1 (May 29,
2008), this is equivalent to CDN$223,225 per QALY, a close
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Figure 4 Cost-effectiveness acceptability curve
(life-years gained).
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estimate to our results. Based primarily on results from the
EVAR-1 trial, Epstein et al. [25] found OR to dominate (less
costs, more QALYs) EVAR. However, the Epstein model pre-
dicted that cumulative mortality was slightly higher for EVAR
patients than for OR patients after 2 years, which may explain
that OR had higher expected QALYs than OR. In contrast, we
assumed that overall mortality was identical after 2 years.
Another difference between our model and Epstein’s model is
related to the way costs and utilities of nonstroke postoperative
complications are modeled. Speciﬁcally, we included MI, CHF,
and renal failure in our model. We also relied on several sources
of evidence to populate our model.
Two older economic models found EVAR to be much more
cost-effective than what was estimated by our model. Bosch et al.
[26] estimated the lifetime cost-effectiveness of EVAR to be
$9905 per QALY in a cohort of 70-year-old males with 5- to
6-cm AAA. Because the large RCTs at the time were not yet
published, the clinical model variables used in Bosch’s model
were based on meta-analyses of observational studies. In an
earlier study, Patel et al. [27] estimated the long-term cost per
QALY of EVAR to be $22,826. As there was no published
evidence on comparative intermediate/long-term survival of
EVAR and OR patients at the time of these models, cumulative
mortality for OR and EVAR was not assumed to converge at a
particular point in time.
Like most economic models, our current model has a number
of limitations. While our model used age-speciﬁc utility and
mortality rates, complication rates associated with OR and
EVAR are age independent because of a lack of evidence, which
may impact the results. As shown in our sensitivity analysis,
cost-effectiveness results did not change under various scenarios
(e.g., time horizon, starting age, and utility). Although we cite the
use of a systematic review of RCTs as a strength of our analysis,
the use of these data can also be considered a limitation because
the patient mix in these studies may have included patients at a
low and high risk of postoperative mortality and morbidity.
There is recent evidence that EVAR may be cost-effective com-
pared to OSR in high-risk patients [28]. In Canada, EVAR is
recommended for patients at an intermediate to high risk of
postoperative morbidity and mortality. For patients at a low risk,
OSR remains the standard of care [29]. Other limitations of this
analysis include the reliance of a single source for utility values
after aneurysm repair (assuming no complications) for the two
treatment groups, and the reliance of using a single hospital for
the source of costs of the initial hospitalization. Despite these
limitations, we believe our economic evaluation comparing dif-
ferent treatments for AAA repair provides useful information for
decision-makers.
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